GNI Group (TSE:2160) Moat Score: 3/10 (As of Jul. 08, 2026)


TSE:2160 GNI Group Ltd TSE:2160
86 GF Score
Price 円2,605.00
GF Value 円2,783.89
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is GNI Group Moat Score?

GNI Group TSE:2160 -7.95% 86 Moat Score is 3 as of Jul. 08, 2026. GuruFocus rates TSE:2160 with a GF Score™ of 86/100 and a GF Value™ of 円2,783.89 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,393 Biotechnology companies, GNI Group ranks better than 75.52% on this metric.

GNI Group has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

GNI Group has No Moat: GNI Group operates in a competitive pharmaceutical market with some intellectual property but lacks significant market share, brand strength, and regulatory advantages to establish a durable competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes GNI Group might have No Moat - Very weak/transient advantages.

GNI Group  (TSE:2160) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

GNI Group Moat Score Related Terms

TSE:2160 vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, GNI Group's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GNI Group Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GNI Group's Moat Score distribution charts can be found below:

* The bar in red indicates where GNI Group's Moat Score falls into.


TSE:2160
86GF Score
GNI Group Ltd TSE:2160
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
GNI Group (TSE:2160) has a Moat Score of 3 as of Jul. 08, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, GNI Group ranks #341 out of 1393 companies in the Biotechnology industry, placing it in the top 24.5%.
Is GNI Group's Moat Score too high?
GNI Group's current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. GNI Group's value of 3 is 50% above this industry median. Based on the distribution chart, GNI Group ranks #341 out of 1393 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, GNI Group has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does GNI Group's Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, GNI Group ranks #341 out of 1393 companies for Moat Score. This places GNI Group in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. GNI Group's value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,393 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GNI Group's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GNI Group's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GNI Group stock overvalued right now?
Based on GuruFocus' analysis, GNI Group (TSE:2160) is currently considered Fairly Valued. The stock's GF Value™ is 円2,783.89, compared to a current price of 円2,605.00 — trading 6.4% below its estimated fair value. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. GNI Group's overall GF Score™ is 86/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For GNI Group (TSE:2160), the current Moat Score is 3 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GNI Group (TSE:2160) Overvalued in 2026?

Based on GuruFocus' analysis, GNI Group stock appears to be undervalued. The current stock price of 円2,605.00 is trading 6.4% below its estimated GF Value™ of 円2,783.89. GuruFocus considers GNI Group to be Fairly Valued.

Key valuation signals for TSE:2160:

  • Moat Score: 3
  • GF Value™: 円2,783.89 vs. price of 円2,605.00 (6.4% below fair value)
  • GF Score™: 86/100 with 5 warning signs
  • Industry Position: 50% above the Biotechnology median (#341 of 1393)

No single metric tells the full story. See the TSE:2160 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GNI Group Business Description

Address 2-2-2 Nihonbashi Honcho, 3rd Floor, Nihonbashi Honcho YS Building, Chuo-ku, Tokyo, JPN, 103-0023
GNI Group Ltd is a clinical stage drug development company. It works on the treatment of diseases that are more common in Asia, especially Japan and China. It is engaged in the discovery, development, manufacture, and sale of drugs for the treatment of cancer and inflammatory diseases.
86GF Score

Get the complete analysis for TSE:2160

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円2,605.00
Price
円2,783.89
GF Value